AN2 Therapeutics adopts limited-duration stockholder rights plan after BML accumulates 19.3% stake

AN2 Therapeutics, Inc.

Rights plan triggered by rapid accumulation of 19.3% of ANTX common stock by BML Investment Partners, as disclosed in Aug. 14, 2024 13G/A filing.
One preferred stock purchase right distributed per common share held on Aug. 29, 2024; exercise price $6.50 per one-thousandth of Series A Preferred.
Rights become exercisable if a person or group acquires 20% or more of common stock (including synthetic ownership).
Rights expire Aug. 15, 2025, unless earlier redeemed ($0.01 per right) or exchanged by Board.
Plan designed to protect all stockholders and prevent coercive takeover tactics without paying a control premium.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.